Active not recruitingPHASE2INTERVENTIONAL

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

This study is looking at new ways to treat womb cancer (endometrial cancer) that has come back or hasn't responded well to previous treatments. It's testing different combinations of medications: olaparib with durvalumab, cediranib with durvalumab, and olaparib with capivasertib. It's also looking at cediranib on its own. These drugs work by targeting specific things that cancer cells need to grow and spread. By checking these combinations, researchers hope to find better treatments that can slow down or stop the cancer, potentially improving outcomes for patients.

At a glance

Status

Active not recruiting

Phase

PHASE2

Sponsor

National Cancer Institute (NCI)

Enrolment target

288

Start

27 Sep 2018

Estimated completion

04 Mar 2027

Endometrial Adenocarcinoma Endometrial Mixed Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Undifferentiated Carcinoma Endometrioid Adenocarcinoma Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Results

Results from this study

Posted September 2025

Results have been published for this study.

Primary outcome

Progression-free Survival

Progression-free survival is defined as the time from the date of study enrollment to the investigator-determined date of progression or death due to any cause, whichever occurs first. For individuals who are alive and progression-free, the censored time at risk will be defined as the time from the study enrollment date to the date of the patient's last radiographic disease assessment.

Full results on the registry

What is this study about?

This study is a Phase II clinical trial, which means it's one of the earlier steps in testing new treatments. It focuses on women who have endometrial cancer, also known as womb cancer. Specifically, it's for cancer that has either returned after previous treatment (recurrent) or hasn't responded to earlier treatments (refractory). The main goal is to see if new drug combinations can be more effective than current approaches.

The drugs being tested are olaparib, durvalumab, capivasertib, and cediranib. Olaparib, cediranib, and capivasertib are designed to interfere with processes that cancer cells need to grow, multiply, and repair themselves. Durvalumab is an immunotherapy, which means it works by helping your body's own immune system recognise and fight the cancer cells. By combining these treatments, doctors hope to find a more powerful way to tackle the cancer.

Researchers will be looking at how well these treatments stop the cancer from growing or spreading. They will compare the different drug combinations to see which ones are most effective. This research is important because it could lead to new treatment options for women with endometrial cancer that is difficult to treat.

Key takeaways

This study is for women with recurrent or hard-to-treat womb cancer.
It's testing combinations of new drugs to see if they can slow or stop cancer growth.
The drugs work in different ways to target cancer cells.
Participation involves regular medical tests and taking study medications.
You have the right to leave the study at any time.
This is a Phase II study, an early step in testing new treatments.

Who may be eligible?

This study is for women who have endometrial cancer that has come back or hasn't responded to previous treatments. Your doctor will need to confirm the exact type of cancer you have, and it needs to be one of the specified types like endometrioid adenocarcinoma or serous adenocarcinoma. Unfortunately, certain types of womb cancer, like clear cell or carcinosarcoma, are not included in this study.

To join, your cancer also needs to be measurable, meaning doctors can clearly see and measure at least one tumor using scans like CT or MRI. If your cancer isn't measurable in this way, you might still be eligible if there are other signs of cancer, such as fluid build-up (ascites) or abnormal findings on scans that don't quite fit the 'measurable' definition.

You should have already received at least one course of chemotherapy for your cancer. You must also be 18 years or older and be able to give your informed consent, which means understanding the study and agreeing to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years or older?
Do you have womb cancer that has come back or hasn't responded to previous treatment?
Have you already had at least one course of chemotherapy for your cancer?
Can doctors measure your cancer on scans, or are there other clear signs of it?
Is your cancer one of the specific types listed for this study (e.g., endometrioid adenocarcinoma)?
Are you willing to provide consent and have your health information used for the study?

Answer every question to see your result.

What does participation involve?

If you join this study, you will have several assessments. These will include medical imaging like CT scans, and possibly an echocardiogram (a heart scan) or a special heart scan called a Multigated Acquisition Scan. You might also have blood tests and, in some cases, bone marrow aspirates and biopsies. These tests help doctors monitor your health and how the treatment is working.

The study involves taking one or more of the trial medications: olaparib, durvalumab, capivasertib, or cediranib. You will be assigned to one of the treatment groups. You'll have regular visits to the clinic for check-ups and to receive your treatment. The full duration of your participation will depend on how you respond to the treatment and will be discussed by the study team.

Potential risks and benefits

Participating in a clinical trial might offer potential benefits, such as access to new treatments before they are widely available, and close medical monitoring. However, there are also potential risks, including side effects from the medications, which can vary from mild to severe, and the possibility that the new treatment may not work for you. You will be fully informed of all known side effects before you decide to join. It is very important to remember that participating is entirely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (763)

University of Alabama at Birmingham Cancer Center
Verified postcode
Birmingham, United States
Anchorage Associates in Radiation Medicine
Verified postcode
Anchorage, United States
Anchorage Radiation Therapy Center
Verified postcode
Anchorage, United States
Alaska Breast Care and Surgery LLC
Verified postcode
Anchorage, United States
Alaska Oncology and Hematology LLC
Verified postcode
Anchorage, United States
Alaska Women's Cancer Care
Verified postcode
Anchorage, United States
Anchorage Oncology Centre
Verified postcode
Anchorage, United States
Katmai Oncology Group
Verified postcode
Anchorage, United States
Providence Alaska Medical Center
Verified postcode
Anchorage, United States
Fairbanks Memorial Hospital
Verified postcode
Fairbanks, United States
CTCA at Western Regional Medical Center
Verified postcode
Goodyear, United States
Kingman Regional Medical Center
Verified postcode
Kingman, United States

Common questions

What is endometrial cancer?

Endometrial cancer is a type of cancer that starts in the lining of the womb (uterus). It's also known as womb cancer.

What does 'recurrent or refractory' mean?

Recurrent means the cancer has come back after treatment. Refractory means the cancer hasn't responded well to previous treatments.

What are these new drugs trying to do?

The drugs aim to stop cancer cells from growing and spreading by blocking certain things they need to survive, or by helping your immune system fight them.

Will I know which treatment I'm getting?

Yes, you will be told which specific drug or combination of drugs you will receive as part of the study.

How long will I be in the study if I join?

The length of your participation will depend on how your cancer responds to the treatment and will be discussed in detail by the study team.